Experimental antibody boosts chemo in ovarian cancer trial

NCT ID NCT05605535

Ongoing Disease control Sponsor: CanariaBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or IV disease will receive the combination or a placebo before and after surgery. The main goal is to see if the combination improves progression-free survival at 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Oregovomab (an experimental antibody) plus chemotherapy (paclitaxel and carboplatin)
What this could lead to: If it works, this could lead to a new treatment option that helps control advanced ovarian cancer for longer before surgery.
What could go wrong: This is a mid-stage trial with only 88 participants, so results may not apply to everyone. The drug could cause side effects or not improve outcomes compared to chemo alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma ovarian epithelial tumor ovarian serous adenocarcinoma peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FALLOPIAN TUBE NEOPLASMS OVARIAN CANCER OVARIAN NEOPLASM EPITHELIAL OVARIAN SEROUS ADENOCARCINOMA PERITONEAL CARCINOMA

Contacts and locations

Locations

Amrita Institute of Medical Sciences

Kochi, Kerala, 682041, India
Himalaya Cancer Hospital and Research Institute

Vadodara, Gujarat, India
Institute of Medical Sciences, BHU

Varanasi, Uttar Pradesh, 221005, India
JIPMER

Puducherry, Puducherry, 605006, India
KLES Dr. Prabhakar Kore Hospital and Medical Research Centre

Belagavi, Karnataka, 590010, India
Kailash Cancer Hospital and Research Centre

Vadodara, Gujarat, India
King George Hospital

Visakhapatnam, Andhra Pradesh, India
King Georges Medical University

Lucknow, Uttar Pradesh, 226003, India
MNJ Cancer Hospital

Hyderabad, Telangana, 500004, India
Omega Hospitals

Visakhapatnam, Andhra Pradesh, 530040, India
Regional Cancer Centre, Medical College

Trivandrum, Kerala, 695011, India
Saveetha Medical College and Hospitals

Chennai, Tamil Nadu, 602105, India
Sri Ram Cancer Hospital

Jaipur, Rajasthan, 302022, India
Sri Ramchandra Medical Centre

Chennai, Tamil Nadu, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.